Adjuvant Capecitabine Plus Oxaliplatin Following D2 Gastrectomy May Be Effective for Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, adjuvant capecitabine in combination with oxaliplatin after undergoing a D2 gastrectomy is a viable option for patients with operable stage 2 or 3 gastric cancer.

For the phase 3, open-label CLASSIC trial, researchers sought to investigate whether adjuvant capecitabine plus oxaliplatin compared with observation after D2 gastrectomy improves survival in patients with stage 2 or 3 gastric cancer.

Researchers randomly assigned 1,035 patients with stage 2-3B gastric cancer who underwent curative D2 gastrectomy to receive either adjuvant chemotherapy or observation. Participants that received chemotherapy received eight 3-week cycles of capecitabine 1,000mg/m2 twice daily for 2 weeks and oxaliplatin 130mg/m2 on day 1.

Results showed that 27% of patients in the adjuvant chemotherapy group achieved a 3-year disease-free survival compared with 39% among those that received observation only (HR = 0.58, 95% CI, 0.47 - 0.72; P < 0.0001).

Among those in the chemotherapy group, 68% were estimated to achieve a 5-year disease-free survival versus 53% in the observation group. Estimated 5-year overall survival rates were 78% and 69% in the adjuvant chemotherapy group and observation group, respectively.

miniDOX Chemotherapy for Patients with Advanced Gastric Cancer
Adjuvant capecitabine with oxaliplatin after gastrectomy is a viable option.
The planned interim analysis of CLASSIC showed that adjuvant capecitabine plus oxaliplatin significantly improved disease–free survival, the primary endpoint, compared with observation after D2 gastrectomy. The authors report the 5–year follow–up data from the trial. Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs